Concepedia

Author

Robert Hettle

AstraZeneca (United Kingdom)ORCID

Also Known As

Hettle R, Hettle, R, Hettle, Robert, R Hettle, R. Hettle, Robert Hettle

97

Publications

816

Citations

14

H-Index

16

Concepts

All Affiliations

AstraZeneca (United Kingdom)PAREXEL International (United Kingdom)University of OklahomaAstraZeneca (United States)Oklahoma State University Oklahoma City
RH

About

Robert Hettle is an author at AstraZeneca (United Kingdom) specializing in medicine, oncology, and outcomes research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

91

2

Obstetrics

2

2

66

3

Public Health

1

1

25

4

Emergency Medicine

1

1

25

5

Health Policy

1

1

25

Robert Hettle

×

17

Publications

541

Citations

12

H-Index

YearCitations

The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal

Robert Hettle, Mark Corbett, Sebastian Hinde,

Health Technology Assessment

2017

120

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial

Mark E. Robson, Kathryn J. Ruddy, Seock‐Ah Im,

European Journal of Cancer

2019

84

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

Michael Friedländer, Kathleen N. Moore, Nicoletta Colombo,

The Lancet Oncology

2021

54

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK

Lara J. Wolfson, Anna N. Walker, Robert Hettle,

PLoS ONE

2015

47

Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England

Robert Hettle, Gerard Harty, Schiffon L. Wong

Journal of Medical Economics

2018

38

Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer

Ignace Vergote, Isabelle Ray‐Coquard, Daniel M. Anderson,

European Journal of Cancer

2021

27

Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium

Robert Hettle, Hanne Wouters, Jon G. Ayres,

Respiratory Medicine

2012

25

Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany

Daniel Wirth, R.N. Dass, Robert Hettle

BMC Health Services Research

2017

25

Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States

Dominic Muston, Robert Hettle, Matthew Monberg,

Gynecologic Oncology

2020

22

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy

Luigi Ruffo Codecasa, Mondher Toumi, A D’Ausilio,

Journal of Market Access & Health Policy

2017

17

Page 1